MEI Pharma, Inc. (MEIP) NASDAQ

3.07

+0.29(+10.43%)

Updated at September 10 04:00PM

Currency In USD

MEI Pharma, Inc.

Address

11455 El Camino Real

San Diego, CA 92130

United States of America

Phone

858 369 7100

Sector

Healthcare

Industry

Biotechnology

Employees

28

First IPO Date

December 18, 2003

Key Executives

NameTitlePayYear Born
Mr. Justin J. File CPAActing Chief Executive Officer, Chief Financial Officer & Corporate Secretary614,7001970
Dr. Robert D. MassStrategic Advisor201,6761954
Ms. Anne FreseChief People Officer0N/A
Ms. Yomara Gomez-NaidenSenior Vice President of Operations & Quality0N/A
Ms. Nicole Chyoko IidaVice President of Legal Affairs0N/A
Mr. David A. Walsey J.D., L.L.M.Senior Vice President of Corporate Affairs0N/A

Description

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.